Ipsen and Marengo Therapeutics Inc, a clinical-stage biotech company, announced today the expansion of their ongoing oncology research partnership, to include TriStar...
French biopharma Ipsen and US-based Marengo Therapeutics have formed a strategic partnership that aims to advance two of Marengo’s preclinical immuno-oncology candidates...
French pharma Ipsen has entered into exclusive negotiations for the sale of its global consumer healthcare business to compatriot firm Mayoly Spindler. The move, said...
05.03.2019
- French drugmaker Ipsen has agreed to buy Canada’s Clementia Pharmaceuticals, boosting its rare disease portfolio. Ipsen will pay $1.04 billion for the clinical-stage biotechnology...
26.04.2017
- The chemical industry is the most important supplier of the pharmaceutical industry, but it can´t keep pace with the economic strength and R&D intensity of pharma. This underlines...
15.02.2017
- French pharmaceutical producer Sanofi has agreed to sell five consumer healthcare products in certain European territories to compatriot drugmaker Ipsen for €83 million. The cash...
12.01.2017
- French drugmaker Ipsen has signed a definitive agreement to buy the global oncology assets of US-based Merrimack Pharmaceuticals in a deal worth potentially more than $1 billion...
07.03.2016
- French pharmaceutical company Ipsen is paying up to $855 million for the rights to Exelixis’ cancer drug Cabozantinib. Under the deal, Exelixis gains exclusive commercialization...
